Last10K.com

Aeolus Pharmaceuticals, Inc. (AOLS) SEC Filing 10-Q Quarterly report for the period ending Thursday, June 30, 2016

Aeolus Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1261734 Ticker: AOLS
Document and Entity Information - shares
9 Months Ended
Jun. 30, 2016
Aug. 15, 2016
Document And Entity Information  
Entity Registrant NameAEOLUS PHARMACEUTICALS, INC. 
Entity Central Index Key0001261734 
Document Type10-Q 
Document Period End DateJun. 30, 2016 
Amendment Flagfalse 
Current Fiscal Year End Date--09-30 
Is Entity a Well-known Seasoned Issuer?No 
Is Entity a Voluntary Filer?No 
Is Entity's Reporting Status Current?Yes 
Entity Filer CategorySmaller Reporting Company 
Entity Common Stock, Shares Outstanding 152,085,825
Document Fiscal Period FocusQ3 
Document Fiscal Year Focus2016 

View differences made from one quarter to another to evaluate Aeolus Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aeolus Pharmaceuticals, Inc..

Continue

Assess how Aeolus Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aeolus Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Balance Sheets (unaudited) (parenthetical)
Condensed Consolidated Statements Of Cash Flows (unaudited)
Condensed Consolidated Statements Of Operations (unaudited)
A. Organization, Business And Summary Of Significant Accounting Policies
A. Organization, Business And Summary Of Significant Accounting Policies (details 1)
A. Organization, Business And Summary Of Significant Accounting Policies (details Narrative)
A. Organization, Business And Summary Of Significant Accounting Policies (details)
A. Organization, Business And Summary Of Significant Accounting Policies (policies)
A. Organization, Business And Summary Of Significant Accounting Policies (tables)
B. Liquidity
C. Stockholders' Equity
C. Stockholders' Equity (deficit) (details Narrative)
C. Stockholders' Equity (details 1)
C. Stockholders' Equity (details)
C. Stockholders' Equity (tables)
D. Stock-based Compensation
D. Stock-based Compensation (details 1)
D. Stock-based Compensation (details 2)
D. Stock-based Compensation (details 3)
D. Stock-based Compensation (details Narrative)
D. Stock-based Compensation (details)
D. Stock-based Compensation (tables)
E. Net Income (loss) Per Common Share
E. Net Income (loss) Per Common Share (details Narrative)
E. Net Income (loss) Per Common Share (details)
E. Net Income (loss) Per Common Share (tables)
F. Debt
G. Recently Issued Accounting Pronouncements
H. Commitments

Material Contracts, Statements, Certifications & more

Aeolus Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: AOLS
CIK: 1261734
Form Type: 10-Q Quarterly Report
Accession Number: 0001102624-16-003292
Submitted to the SEC: Mon Aug 15 2016 4:10:40 PM EST
Accepted by the SEC: Mon Aug 15 2016
Period: Thursday, June 30, 2016
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/aols/0001102624-16-003292.htm